MK-1597: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 12001785 |
| CHEMBL ID | 1269743 |
| MeSH ID | M0573254 |
| Synonym |
|---|
| bdbm50328905 |
| CHEMBL1269743 , |
| (3r,4s)-n-(2-chloro-5-(2-methoxyethyl)benzyl)-n-cyclopropyl-4-(6-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)pyridin-3-yl)piperidine-3-carboxamide |
| mk-1597 |
| act-178882 |
| unii-ta1atu85yc |
| act 178882 |
| CS-7478 |
| HY-U00262 |
| (3'r,4's)-6-[2-(2,6-dichloro-4-methyl-phenoxy)-ethoxy]-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-3'-carboxylic acid [2-chloro-5-(2-methoxy-ethyl)-benzyl]-cyclopropyl-amide |
| TA1ATU85YC , |
| 3-piperidinecarboxamide, n-((2-chloro-5-(2-methoxyethyl)phenyl)methyl)-n-cyclopropyl-4-(6-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)-3-pyridinyl)-, (3r,4s)- |
| 1007392-69-9 |
| act 178882 [who-dd] |
| (3r,4s)-n-((2-chloro-5-(2-methoxyethyl)phenyl)methyl)-n-cyclopropyl-4-(6-(2-(2,6-dichloro-4-methyl-phenoxy)ethoxy)-3-pyridyl)piperidine-3-carboxamide |
| (3r,4s)-n-[[2-chloro-5-(2-methoxyethyl)phenyl]methyl]-n-cyclopropyl-4-[6-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]pyridin-3-yl]piperidine-3-carboxamide |
| AKOS040741045 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Mild headache and diarrhea were the most common adverse events in the single- and multiple-dose parts, respectively." | ( Age and sex effects on the single- and multiple-dose safety and pharmacokinetics of the new renin inhibitor ACT-178882. Dingemanse, J; Nicolas, L, 2013) | 0.39 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Following single doses of ACT-178882, t1/2 and tmax varied from 18." | ( Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam. Binkert, C; Dingemanse, J; Nicolas, L, 2013) | 0.39 |
| " In the single-dose part and independent of sex, values for Cmax and AUC0-∞ were about 85% higher in elderly compared with young subjects, and t1/2 was about 5 h longer (29." | ( Age and sex effects on the single- and multiple-dose safety and pharmacokinetics of the new renin inhibitor ACT-178882. Dingemanse, J; Nicolas, L, 2013) | 0.39 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "In this open-label, two-way crossover, drug-drug interaction study, healthy young male subjects received treatments A and B in a randomized fashion." | ( Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. Dingemanse, J; Nicolas, L, 2013) | 0.39 |
| " Treatment with ACT-178882 alone or in combination with diltiazem was safe and well tolerated." | ( Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. Dingemanse, J; Nicolas, L, 2013) | 0.39 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the multiple-ascending-dose part, subjects were dosed with midazolam on days -2, 2, and 12 to investigate interactions with CYP3A4." | ( Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam. Binkert, C; Dingemanse, J; Nicolas, L, 2013) | 0.39 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Renin | Homo sapiens (human) | IC50 (µMol) | 0.0001 | 0.0000 | 0.7796 | 8.2000 | AID526107 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | Activity | 3.9000 | 0.4280 | 2.1647 | 4.5000 | AID526110; AID526111 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Renin | Homo sapiens (human) |
| extracellular space | Renin | Homo sapiens (human) |
| plasma membrane | Renin | Homo sapiens (human) |
| apical part of cell | Renin | Homo sapiens (human) |
| extracellular space | Renin | Homo sapiens (human) |
| cytoplasm | Cytochrome P450 3A4 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Cytochrome P450 3A4 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Cytochrome P450 3A4 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID526112 | Ratio of IC50 for CYP3A4 at to IC50 for CYP3A4 after 30 mins preincubation in presence of liver microsome | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| AID526109 | Ratio of IC50 for renin in buffer to IC50 for renin in plasma | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| AID526110 | Inhibition of CYP3A4 using midazolam as substrate | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| AID526115 | Half life in transgenic rat harboring human angiotensinogen and human renin gene at 3 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| AID526114 | Induction of area between the curves in transgenic rat harboring human angiotensinogen and human renin gene at 3 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| AID526111 | Inhibition of CYP3A4 using testosterone as substrate | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| AID526113 | Induction of maximal mean arterial pressure in transgenic rat harboring human angiotensinogen and human renin gene at 3 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| AID526117 | Oral bioavailability in transgenic rat harboring human angiotensinogen and human renin gene at 3 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| AID526116 | Clearance in transgenic rat harboring human angiotensinogen and human renin gene at 3 mg/kg, po | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| AID526107 | Inhibition of renin in buffer | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| AID526108 | Inhibition of renin in plasma | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Piperidine-based renin inhibitors: upper chain optimization. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (57.14%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (42.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||